Analyst Price Targets — ZYME
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 11:16 am | Asthika Goonewardene | Truist Financial | $40.00 | $25.85 | TheFly | Zymeworks initiated with a Buy at Truist |
| December 12, 2025 10:20 am | — | Wells Fargo | $33.00 | $24.93 | TheFly | Zymeworks upgraded to Overweight from Equal Weight at Wells Fargo |
| December 3, 2025 10:03 am | — | JMP Securities | $32.00 | $25.10 | TheFly | Zymeworks initiated with an Outperform at Citizens JMP |
| November 19, 2025 10:31 am | Eva Verdejo | Wells Fargo | $25.00 | $22.99 | StreetInsider | Zymeworks (ZYME) PT Raised to $25 at Wells Fargo |
| November 19, 2025 9:27 am | Stephen Willey | Stifel Nicolaus | $40.00 | $22.99 | StreetInsider | Zymeworks (ZYME) PT Raised to $40 at Stifel |
| November 17, 2025 7:36 pm | Andrew Berens | Leerink Partners | $37.00 | $23.90 | TheFly | Zymeworks price target raised to $37 from $24 at Leerink |
| October 14, 2025 10:07 am | Robert Burns | H.C. Wainwright | $26.00 | $18.11 | TheFly | Zymeworks upgraded to Buy from Neutral at H.C. Wainwright |
| November 21, 2024 2:22 pm | Andrew Berens | Leerink Partners | $26.00 | $13.68 | StreetInsider | Zymeworks (ZYME) PT Raised to $26 at Leerink Partners |
| November 1, 2024 9:13 am | Derek Archila | Wells Fargo | $12.00 | $13.28 | StreetInsider | Wells Fargo Downgrades Zymeworks (ZYME) to Equal Weight |
| October 28, 2024 7:47 am | Stephen Willey | Stifel Nicolaus | $28.00 | $13.11 | StreetInsider | Zymeworks (ZYME) PT Raised to $28 at Stifel |
Latest News for ZYME
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.31 per share a year ago.
NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and…
VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and…
VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a summary of recent business highlights.
Redmile Group sold 3,214,096 ZYME shares, estimated at $70.10 million based on quarterly average prices. Meanwhile, the quarter-end value of the Zymeworks stake decreased by $50.35 million, reflecting both stock sales and price changes.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZYME.
U.S. House Trading
No House trades found for ZYME.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.